Results 1 to 10 of about 1,523,590 (132)
The Brugada Type 1 Electrocardiogram and Ventricular Tachycardia With High-Dose Amitriptyline
JACC: Case Reports, 2021 A 32-year-old woman with anorexia nervosa experienced ventricular tachycardia while on therapeutic-dose amitriptyline despite normal blood tests, imaging, and intracardiac recordings.
Ji-Jian Chow, MRCP +2 more
doaj +1 more source
Frontiers in Pharmacology, 2020 Aims: Conflicting data exist on whether an association exists between antidepressants and the risk of major adverse cardiovascular events (MACEs) in patients with depression.
Ha Young Jang +8 more
doaj +1 more source
Ferulic acid as a therapeutic agent in depression: Evidence from preclinical studies
CNS Neuroscience &Therapeutics, Volume 29, Issue 9, Page 2397-2412, September 2023., 2023 Abstract Depression is a common but severe mood disorder with a very high prevalence across the general population. Depression is of global concern and poses a threat to human physical and mental health. Ferulic acid (FA) is a natural active ingredient that has antioxidative, anti‐inflammatory, and free radical scavenging properties.
Xiaoyu Dong, Dongxue Zhao
wiley +1 more source
iMeta, Volume 2, Issue 3, August 2023., 2023 We successfully isolated Maca‐EVs using ultracentrifugation and tested its antidepressant effects in the unpredictable chronic mild stress mice. Maca‐EVs increased serum serotonin (5‐HT) levels probably via the gut microbiota and metabolism modulation.
Rui Hong +14 more
wiley +1 more source
Increased risk of depression after Guillain‐Barré syndrome
Muscle &Nerve, Volume 67, Issue 6, Page 497-505, June 2023., 2023 Abstract Introduction/Aims Guillain‐Barré syndrome (GBS) is a potentially life‐threatening disorder, and some patients may develop subsequent depression related to traumatic stress or permanent loss of motor function. We determined the short‐term (0 to 2 years) and long‐term (>2 years) risk of depression after GBS.
Lotte Sahin Levison +2 more
wiley +1 more source
Novel drug developmental strategies for treatment‐resistant depression
British Journal of Pharmacology, Volume 179, Issue 6, Page 1146-1186, March 2022., 2022 Major depressive disorder is a leading cause of disability worldwide. Because conventional therapies are ineffective in many patients, novel strategies are needed to overcome treatment‐resistant depression (TRD). Limiting factors of successful drug development in the last decades were the lack of (1) knowledge of pathophysiology, (2) translational ...
Éva Borbély +5 more
wiley +1 more source
Antidepressant use and stroke or mortality risk in the elderly
European Journal of Neurology, Volume 29, Issue 2, Page 469-477, February 2022., 2022 In real‐world data of the elderly population, it was found that the risk of experiencing stroke or death in antidepressant users during and up to 1 year after exposure was higher compared to non‐users, even after adjustment for possible confounders. Abstract Background and purpose Current evidence on antidepressant‐related stroke or mortality risk is ...
Begüm Irmak Ön +7 more
wiley +1 more source
Rhabdomyolysis as a manifestation of clomipramine poisoning
São Paulo Medical JournalCONTEXT: Tricyclic antidepressive agents are widely used in suicide attempts and present a variety of deleterious effects. Rhabdomyolysis is a rare complication of such poisoning.
Nathalie Oliveira de Santana +1 more
doaj +1 more source
Pharmacologic Treatment of Irritable Bowel Syndrome with Predominant Constipation
The Korean Journal of GastroenterologyIrritable bowel syndrome with predominant constipation (IBS-C) is a functional gastrointestinal disorder characterized by abdominal pain with chronic constipation and abdominal bloating, which could significantly impair the quality of life of patients ...
Dong Hyun Kim +3 more
doaj +1 more source
Risk of gastrointestinal bleeding by specific SSRIs and SNRIs: A systematic review and meta‐analysis
British Journal of Clinical Pharmacology, Volume 92, Issue 3, Page 793-808, March 2026.Aim The purpose of this study is to estimate the risk of gastrointestinal bleeding (GIB) by selective serotonin reuptake inhibitors (SSRIs) and serotonin–norepinephrine reuptake inhibitors (SNRIs) individual agents. Methods A systematic review was conducted for each unique antidepressant (i.e.
Ainhoa Gomez‐Lumbreras +8 more
wiley +1 more source